clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03577704 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
phase II clinical trial | Q42824440 | ||
P582 | end time | 2021-09-30 | |
P4135 | maximum age | 75 | |
P2899 | minimum age | 18 | |
P1132 | number of participants | 90 | |
P4844 | research intervention | calcium oxalate | Q412399 |
cisplatin | Q412415 | ||
carboplatin | Q415588 | ||
paclitaxel | Q423762 | ||
immunological antineoplastic agent | Q50429626 | ||
P6153 | research site | Shanghai East Hospital | Q30296399 |
P1813 | short name | HLX07Ib/II | |
P580 | start time | 2018-08-08 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors. |
Search more.